drugset / Trial / NCT01260753

Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

NCT01260753

Phase 2 Completed 24 enrolled Palau Pharma S.L.U.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to explore the activity of UR-63325 in a model of allergic rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise healthy.

Timeline

Start
2010-12
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified Intranasal
Subject UR-63325 Small molecule